During Tuesday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about Aurinia Pharmaceuticals (AUPH) : "They should be doing better. I want to be careful with that stock," he responded.
More from Investing
These recently downgraded names are displaying both quantitative and technical deterioration.
The S&P 500 and DJIA are convenient benchmarks, but they can hurt your returns if you give them too much weight.
Here's what I found most positive about the market as the week closed out.
I like to identify a chart or two with a nice setup into the next week, and OB falls into that category.